MedTrace Logo

Study of NIB101 in Participants With Advanced Solid Tumors

NCT05192174 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-05-23

No results posted yet for this study

Summary

NIB101-01 study is an open-label, non-randomized Phase 1 study in participants with GM2 positive advanced solid tumor, who failed to available standard of cares to evaluate the safety and tolerability of NIB101.

Conditions

Interventions

BIOLOGICAL

NIB101

NIB101

Sponsors & Collaborators

  • Noile-Immune Biotech, Inc

    lead INDUSTRY

Principal Investigators

  • Noile-Immune Biotech, Inc. · Noile-Immune Biotech, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-24
Primary Completion
2025-05-16
Completion
2025-05-16

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05192174 on ClinicalTrials.gov